Table 1.

Detailed information regarding studies and datasets used in the present study

Exposure or outcome	Preferred names	Source	Ancestry	Participants
Phosphodiesterases
PDE1A	Dual specificity calcium/calmodulin-dependent 3′,5′-cyclic nucleotide phosphodiesterase 1A	PMID: 29875488	European	3301 individuals
PDE2A	cGMP-dependent 3′,5′-cyclic phosphodiesterase	PMID: 29875488	European	3301 individuals
PDE3A	cGMP-inhibited 3′,5′-cyclic phosphodiesterase 3A	PMID: 29875488	European	3301 individuals
PDE4D	cAMP-specific 3′,5′-cyclic phosphodiesterase 4D	PMID: 29875488	European	3301 individuals
PDE5A	cGMP-specific 3′,5′-cyclic phosphodiesterase	PMID: 28240269	European	997 individuals
PDE6D	Retinal rod rhodopsin-sensitive cGMP 3′,5′-cyclic phosphodiesterase subunit delta	PMID: 29875488	European	3301 individuals
PDE7A	High affinity cAMP-specific 3′,5′-cyclic phosphodiesterase 7A	PMID: 29875488	European	3301 individuals
PDE9A	High affinity cGMP-specific 3′,5′-cyclic phosphodiesterase 9A	PMID: 29875488	European	3301 individuals
Psychiatric disorders
AD	Alzheimer’s disease	PMID: 30617256	European	71,880 cases and 383,378 controls
ADHD	Attention-deficit/hyperactivity disorder	PMID: 29325848	European	20,183 cases and 35,191 controls
AN	Anorexia nervosa	PMID: 28494655	European	3495 cases and 10,982 controls
ASD	Autism spectrum disorder	PMID: 30804558	European	18,381 cases and 27,969 controls
BD	Bipolar disorder	PMID: 31043756	European	20,352 cases and 31,358 controls
MDD	Major depressive disorder	PMID: 30718901	European	170,756 cases and 329,443 controls
OCD	Obsessive–compulsive disorder	PMID: 28761083	European	2688 cases and 7,037 controls
SCZ	Schizophrenia	PMID: 25056061	European	35,476 cases and 46,839 controls
TS	Tourette syndrome	PMID: 30818990	European	4819 cases and 9488 controls